John Crowley

64.6k total citations · 11 hit papers
341 papers, 28.4k citations indexed

About

John Crowley is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, John Crowley has authored 341 papers receiving a total of 28.4k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Hematology, 153 papers in Oncology and 141 papers in Molecular Biology. Recurrent topics in John Crowley's work include Multiple Myeloma Research and Treatments (162 papers), Protein Degradation and Inhibitors (71 papers) and Cancer Treatment and Pharmacology (66 papers). John Crowley is often cited by papers focused on Multiple Myeloma Research and Treatments (162 papers), Protein Degradation and Inhibitors (71 papers) and Cancer Treatment and Pharmacology (66 papers). John Crowley collaborates with scholars based in United States, United Kingdom and Japan. John Crowley's co-authors include Bart Barlogie, Kari Chansky, Ramón Rami–Porta, Dorothy J. Giroux, Peter Goldstraw, Elias Anaissie, Valerie W. Rusch, Frits van Rhee, Guido Tricot and John D. Shaughnessy and has published in prestigious journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

John Crowley

330 papers receiving 27.7k citations

Hit Papers

The IASLC Lung Cancer Sta... 1977 2026 1993 2009 2007 1999 2001 2006 2001 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
    2007 2.9k citations John Crowley, Kari Chansky et al. Journal of Thoracic Oncology profile →
  2. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
    1999 2.0k citations Elias Anaissie, Madhav V. Dhodapkar et al. profile →
  3. Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
    2001 923 citations John Crowley, Robert B. Livingston et al. Journal of Clinical Oncology profile →
  4. The molecular classification of multiple myeloma
    2006 783 citations Fenghuang Zhan, Joshua Epstein et al. Blood profile →
  5. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
    2001 712 citations John Crowley et al. profile →
  6. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
    2006 532 citations Bart Barlogie, Guido Tricot et al. profile →
  7. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
    2015 530 citations John Crowley et al. Journal of Thoracic Oncology profile →
  8. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    2002 507 citations Fenghuang Zhan, Maurizio Zangari et al. Blood profile →
  9. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
    2007 482 citations John Crowley, Dorothy J. Giroux et al. Journal of Thoracic Oncology profile →
  10. The International Association for the Study of Lung Cancer Lung Cancer Staging Project
    2015 455 citations Kari Chansky, John Crowley et al. Journal of Thoracic Oncology profile →
  11. Covariance Analysis of Heart Transplant Survival Data
    1977 326 citations John Crowley et al. Journal of the American Statistical Association profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
John Crowley 12.9k 11.0k 10.4k 9.7k 2.5k 341 28.4k
Glenn Heller 7.0k 0.5× 4.7k 0.4× 4.6k 0.4× 6.6k 0.7× 3.1k 1.3× 301 20.5k
Richard Pazdur 19.8k 1.5× 3.5k 0.3× 10.6k 1.0× 10.3k 1.1× 5.2k 2.1× 596 37.7k
Christoph Zielinski 10.1k 0.8× 2.0k 0.2× 5.0k 0.5× 5.7k 0.6× 2.6k 1.1× 499 20.8k
John J. Crowley 8.0k 0.6× 2.8k 0.3× 3.9k 0.4× 8.8k 0.9× 1.8k 0.7× 195 17.8k
Donna Neuberg 14.0k 1.1× 12.4k 1.1× 14.4k 1.4× 4.1k 0.4× 4.4k 1.8× 719 46.3k
George D. Demetri 11.1k 0.9× 3.5k 0.3× 6.6k 0.6× 23.7k 2.5× 3.7k 1.5× 346 38.0k
Salvatore Siena 26.8k 2.1× 3.4k 0.3× 7.6k 0.7× 12.2k 1.3× 7.0k 2.9× 534 37.8k
Thomas E. Witzig 13.5k 1.0× 9.6k 0.9× 11.2k 1.1× 2.8k 0.3× 1.8k 0.7× 778 34.1k
Richard Greil 10.9k 0.8× 2.3k 0.2× 5.3k 0.5× 4.1k 0.4× 3.9k 1.6× 731 20.1k
Terry L. Smith 7.7k 0.6× 3.6k 0.3× 2.8k 0.3× 2.6k 0.3× 4.2k 1.7× 154 16.0k

Countries citing papers authored by John Crowley

Since Specialization
Citations

This map shows the geographic impact of John Crowley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Crowley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Crowley more than expected).

Fields of papers citing papers by John Crowley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Crowley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Crowley. The network helps show where John Crowley may publish in the future.

Co-authorship network of co-authors of John Crowley

This figure shows the co-authorship network connecting the top 25 collaborators of John Crowley. A scholar is included among the top collaborators of John Crowley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Crowley. John Crowley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Raine, Tim, Silvio Danese, Stefan Schreiber, et al.. (2024). DOP64 Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s Disease: Post hoc results from the phase 3b SEQUENCE trial. Journal of Crohn s and Colitis. 18(Supplement_1). i189–i189. 2 indexed citations
3.
Matsui, Shigeyuki & John Crowley. (2017). Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design. Clinical Cancer Research. 24(5). 994–1001. 9 indexed citations
4.
Barlogie, Bart, Alan Mitchell, Frits van Rhee, et al.. (2014). Curing myeloma at last: defining criteria and providing the evidence. Blood. 124(20). 3043–3051. 169 indexed citations
5.
Heuck, Christoph, Jackie Szymonifka, John D. Shaughnessy, et al.. (2012). Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1. Clinical Cancer Research. 18(19). 5499–5506. 13 indexed citations
6.
7.
8.
Morel, Pierre, Alain Duhamel, Paolo G. Gobbi, et al.. (2009). International prognostic scoring system for Waldenström macroglobulinemia. Blood. 113(18). 4163–4170. 228 indexed citations
9.
Davies, Angela M., Kari Chansky, Primo N. Lara, et al.. (2009). Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339). Journal of Thoracic Oncology. 4(1). 87–92. 64 indexed citations
10.
Burington, Bart, Bart Barlogie, Fenghuang Zhan, John Crowley, & John D. Shaughnessy. (2008). Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma. Clinical Cancer Research. 14(15). 4821–4829. 35 indexed citations
11.
Haessler, Jeffrey, John D. Shaughnessy, Fenghuang Zhan, et al.. (2007). Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling. Clinical Cancer Research. 13(23). 7073–7079. 75 indexed citations
12.
Rusch, Valerie W., Dorothy J. Giroux, Michael Kraut, et al.. (2001). Induction chemoradiation and surgical resection for non–small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). Journal of Thoracic and Cardiovascular Surgery. 121(3). 472–483. 187 indexed citations
13.
14.
15.
Antman, Karen H., John Crowley, S P Balcerzak, et al.. (1998). A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.. PubMed. 82(7). 1288–95. 25 indexed citations
16.
Barlogie, Bart, Sundar Jagannath, S. Naucke, et al.. (1998). Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone. 1101–11071. 1 indexed citations
17.
George, Stephanie M., John Crowley, S S Ellenberg, et al.. (1993). Discussion: Stephen George, a survey of monitoring practices in cancer clinical trials: Stephanie Green and John Crowley, data monitoring committees for Southwest Oncology Group clinical trials. Statistics in Medicine. 12. 457–459. 2 indexed citations
18.
Crowley, John, et al.. (1991). Evaluation of amonafide in refractory and relapsing multiple myeloma. Anti-Cancer Drugs. 2(3). 247–250. 3 indexed citations
19.
Brookmeyer, Ron & John Crowley. (1982). A k -Sample Median Test for Censored Data. Journal of the American Statistical Association. 77(378). 433–440. 52 indexed citations
20.
Gould, Michael N., Randy L. Jirtle, John Crowley, & Kelly H. Clifton. (1978). Reevaluation of the number of cells involved in the neutron induction of mammary neoplasms.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(1). 189–92. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Glenn Heller Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Christoph Zielinski Breakdown of academic impact, for papers by John J. Crowley Breakdown of academic impact, for papers by Donna Neuberg Breakdown of academic impact, for papers by George D. Demetri Breakdown of academic impact, for papers by Salvatore Siena Breakdown of academic impact, for papers by Thomas E. Witzig Breakdown of academic impact, for papers by Richard Greil Breakdown of academic impact, for papers by Terry L. Smith
Rankless by CCL
2026